Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Our differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of our bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.
The company’s product candidates, AL101 and AL102, were licensed into Ayala from Bristol Myers Squibb. Our lead product candidate AL101 is currently in Phase 2 clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma, for patients bearing Notch-activating mutations. Our second product candidate AL102 is being developed for the treatment of desmoid tumors. In addition, we are collaborating with Novartis to develop AL102 for the treatment of multiple myeloma in combination with Novartis’ B-cell maturation antigen (BCMA) targeting therapies. The company is based in the US and Israel.
The company’s product candidates, AL101 and AL102, were licensed into Ayala from Bristol Myers Squibb. Our lead product candidate AL101 is currently in Phase 2 clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma, for patients bearing Notch-activating mutations. Our second product candidate AL102 is being developed for the treatment of desmoid tumors. In addition, we are collaborating with Novartis to develop AL102 for the treatment of multiple myeloma in combination with Novartis’ B-cell maturation antigen (BCMA) targeting therapies. The company is based in the US and Israel.
Location: United States, Delaware, Wilmington
Employees: 11-50
Total raised: $30M
Founded date: 2017
Investors 4
| Date | Name | Website |
| - | aMoon Fund | amoon.fund... |
| - | Shavit Cap... | shavitcapi... |
| - | Israel Bio... | ibf.fund |
| - | Arc Ventur... | arc-vc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.05.2019 | Series B | $30M | - |
Mentions in press and media 10
| Date | Title | Description |
| 19.05.2025 | OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals | OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Phar... |
| 27.03.2024 | Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome | MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL1... |
| 06.02.2024 | Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals | AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile BOTHELL, Wash. and MONMOUTH JUNCTION, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) — Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to deve... |
| 19.02.2021 | Ayala Pharmaceuticals Announces $25 Million Strategic Financing | Funding Extends Cash Runway through Multiple Expected Value Drivers Into 2023 Funds Expected to Support the Recently Announced Accelerated Development of AL102 for the Treatment of Desmoid Tumors into Pivotal Phase 2/3 Study REHOVOT, Israel... |
| 30.06.2020 | ‘Covid Put Everything On Steroids,’ Says Prominent Healthtech Investor | When VC aMoon was established in 2017, “the premise was to invest heavily in the convergence of technology and biology, healthcare and data,” says Dr. Yair Schindel, its Managing Partner. Schindel and Marius Nacht, the other founder of the ... |
| 12.05.2020 | Ayala Pharmaceuticals Announces Closing of Initial Public Offering | Ayala is an Arc Ventures portfolio company since 2018 . The official press release can be found on the company’s website. |
| 28.05.2019 | Ayala Pharmaceuticals Raises $30 Million in Series B Financing | REHOVOT, Israel & WILMINGTON, Del.--(BUSINESS WIRE)--Ayala Pharmaceuticals, Inc., a clinical-stage company developing medicines for cancers that are genetically defined, today announced the successful completion of a $30 million Series ... |
| 28.05.2019 | Ayala Pharmaceuticals Secures $30M in Series B Funding | Ayala Pharmaceuticals, Inc., a Wilmington, DE-based clinical-stage company developing medicines for cancers that are genetically defined, closed a $30m Series B financing. The round was led by Novartis with participation from SBI JI Innovat... |
| 28.05.2019 | Ayala Pharmaceuticals Raises $30 Million in Series B Financing | REHOVOT, Israel & WILMINGTON, Del.--(BUSINESS WIRE)--Ayala Pharmaceuticals, Inc., a clinical-stage company developing medicines for cancers that are genetically defined, today announced the successful completion of a $30 million Series ... |
| 25.05.2019 | Ayala Pharmaceuticals Raises $30 Million | - |